Placebo to FTC/TDF

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIV Pre-Exposure ProphylaxisHIV Preexposure ProphylaxisHIV-IHuman Immunodeficiency Virus (HIV)Human Immunodeficiency Virus Type 1Prophylaxis

Phase 3

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

TerminatedNCT04644029

Merck Sharp & Dohme LLCHIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis

Start: 2021-02-24End: 2024-06-11Updated: 2026-02-04

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

TerminatedNCT04652700

Merck Sharp & Dohme LLCHIV Preexposure Prophylaxis

Start: 2021-03-15End: 2023-08-04Updated: 2025-01-13

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

RecruitingNCT07044297

Merck Sharp & Dohme LLCHIV Pre-Exposure Prophylaxis, Human Immunodeficiency Virus (HIV)

Start: 2025-07-31End: 2027-07-22Target: 4390Updated: 2026-03-30

Related Papers

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

UNC Libraries2026-03-26

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.

2026-03-14